A recent webinar hosted by members of the Mobilise-D consortium revealed that construct validity was supported for multiple digital mobility outcomes (DMOs). The clinical validation studies involved almost 2,400 patients and evaluated 24 DMOs across 4 participant cohorts: chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), Parkinson’s (PD), and proximal femur fracture (PFF). Construct validity testing assessed convergent, divergent, and known-groups validi

Productivity in biopharmaceutical R&D is driven by a combination of effectiveness (doing the right things) and efficiency (doing things right). The framework below was recently presented by Roche at the recent Digital Biomarkers conference in Basel, and illustrates a number of levers firms can use to improve productivity. We have used it to show how real-world mobility data can improve R&D productivity in multiple ways, namely enhancing asset value, increasing success rates,

Mobility is an excellent indicator of overall heath, so much so that it has been referred to as the '6th' or 'functional' vital sign. The post explains why and how the data could be used to provide early indications of neurological decline and future quality of life issues.